Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: Review of the literature and clinical suggestions

CNS Drugs

Volumn 24, Issue 3, 2010, Pages 193-206

  Hasnain, Mehrul ^a   Vieweg, W Victor R ^b,c   Fredrickson, Sonja K ^b  

^a Sir Thomas Roddick Hospital Stephenville   (Canada)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CIMETIDINE; CLOZAPINE; FUROSEMIDE; HALOPERIDOL; IODINATED CONTRAST MEDIUM; METFORMIN; NIFEDIPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SIBUTRAMINE; SULPIRIDE; TRIFLUOPERAZINE; VALPROIC ACID;

ABDOMINAL DISCOMFORT; BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET RESTRICTION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOEDUCATION; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEAKNESS; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; GLUCOSE METABOLISM DISORDERS; GUIDELINES AS TOPIC; HUMANS; INSULIN RESISTANCE; MENTAL DISORDERS; METFORMIN; PUBMED; RISK FACTORS; WEIGHT GAIN;

EID: 76949084178     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11530130-000000000-00000     Document Type: Review

References (98)

1. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005 Nov; 19 (6 Suppl.): 16-27
2. Hasnain M, Vieweg WV, Fredrickson SK, et al. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009 Feb; 3 (1): 5-15
3. Newcomer JW, Haupt DW. The metabolic effects of anti-psychotic medications. Can J Psychiatry 2006 Jul; 51 (8): 480-491
4. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007 Jul; 93 (1-3): 117-130 (Pubitemid 46817944)
5. Spina E, Cavallaro R. The pharmacology and safety of pali-peridone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf 2007 Nov; 6 (6): 651-662
6. Hennekens CH, Hennekens AR, Hollar D, et al. Schizo-phrenia and increased risks of cardiovascular disease. Am Heart J 2005 Dec; 150 (6): 1115-1121
7. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006 Jul; 14 (4): 212-222
8. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004 Nov; 61 (11): 1107-1115
9. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 2005 Dec; 20 Suppl. 4: S335-9
10. Gough SC, O'Donovan MC. Clustering of metabolic co-morbidity in schizophrenia: a genetic contribution? J Psy-chopharmacol 2005 Nov; 19 (6 Suppl.): 47-55
11. Tsang TM, Huang JT, Holmes E, et al. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res 2006 Apr; 5 (4): 756-760
12. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endo-crinologists; North American Association for the Study of Obesity. Consensus development conference on anti-psychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27 (2): 596-601
13. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry 2007; 68 Suppl. 6: 14-23
14. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009 Feb; 166 (2): 152-163
15. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizo-phrenia:a meta-analysis. Lancet 2009 Jan 3;373 (9657): 31-41
16. Baptista T, ElFakih Y, Uzcategui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008; 22 (6): 477-495
17. Faulkner G, Cohn TA. Pharmacologic and nonpharmaco-logic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006 Jul; 51 (8): 502-511
18. Top 200 generic drugsbyunitsin 2007 [online]. Available from URL: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard// drugtopics/072008/491181/article.pdf [Accessed 2009 Jan 10]
19. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 Feb 7; 346 (6): 393-403
20. Ratner RE. An update on the Diabetes Prevention Program. Endocr Pract 2006 Jan; 12 Suppl. 1: 20-24
21. Ramachandran A, Snehalatha C, Mary S, et al., Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006 Feb; 49 (2): 289-297
22. Lebinger TG. Metformin and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2007 Apr; 14 (2): 132-140
23. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008 May; 93 (5): 1841-1845
24. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999 Jul; 100 (1): 3-16 (Pubitemid 29309192)
25. Arman S, Sadramely MR, Nadi M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperi-done in children and adolescents. Saudi Med J 2008 Aug; 29 (8): 1130-1134
26. Baptista T, Hernandez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001 Aug; 62 (8): 653-655
27. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006 Mar; 51 (3): 192-196
28. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multi-centric, double-blind, placebo-controlled trial. Schizophr Res 2007 Jul; 93 (1-3): 99-108
29. Baptista T, Uzcategui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008 May 30; 159 (1-2): 250-253
30. Chen CH, Chiu CC, Huang MC, et al. Metformin for meta-bolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008 May 15; 32 (4): 925-931
31. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006 Dec; 163 (12): 2072-2079
32. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002 Apr; 159 (4): 655-657
33. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008 Jan 9; 299 (2): 185-193
34. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008 Mar; 165 (3): 352-358
35. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993 Jun 16; 269 (23): 3015-3023
36. West DS, Elaine PT, Bursac Z, et al. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring) 2008 Jun; 16 (6): 1413-1420
37. Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006 Oct; 61 (10): 1075-1081
38. Levri KM, Slaymaker E, Last A, et al. Metformin as treat-ment for overweight and obese adults: a systematic review. Ann Fam Med 2005 Sep; 3 (5): 457-461
39. Salpeter SR, Buckley NS, Kahn JA, et al. Meta-analysis: metformin treatment in persons at risk for diabetes melli-tus. Am J Med 2008 Feb; 121 (2): 149-157
40. Atabek ME, Pirgon O. Use of metformin in obese adoles-cents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008 Apr; 21 (4): 339-348
41. Trolle B, Flyvbjerg A, Kesmodel U, et al. Efficacy of met-formin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007 Nov; 22 (11): 2967-2973
42. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999 Apr; 22 (4): 623-634
43. Holt RI, Peveler RC. Antipsychotic drugs and diabetes: an application of the Austin Bradford Hill criteria. Dia-betologia 2006 Jul; 49 (7): 1467-1476
44. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008 Apr; 28 (2): 132-137
45. de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007 May; 92 (1-3): 95-102
46. Cohen D, Stolk RP, Grobbee DE, et al. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006 Apr; 29 (4): 786-791
47. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002 Apr; 159 (4): 561-566
48. Hammerman A, Dreiher J, Klang SH, et al. Antipsychotics and diabetes: an age-related association. Ann Pharmaco-ther 2008 Sep; 42 (9): 1316-1322
49. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13 (1): 27-35
50. Kim SF, Huang AS, Snowman AM, et al. From the cover: antipsychotic drug-induced weight gain mediated by his-tamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007 Feb 27; 104 (9): 3456-3459
51. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic-induced weight gain: mechanisms and genetics. J Psychopharmacol 2006 Jul; 20 (4 Suppl.): 15-18
52. Sentissi O, Epelbaum J, Olie JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different anti-psychotics treatment: a review. Schizophr Bull 2008 Nov; 34 (6): 1189-1199
53. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occu-pancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005Oct; 20(5): 368-378
54. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005 Jan; 62 (1): 19-28
55. Murashita M, Kusumi I, Hosoda H, et al. Acute adminis-tration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuro-endocrinology 2007 Aug; 32 (7): 777-784
56. Tulipano G, Rizzetti C, Bianchi I, et al. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary- adrenal axis activation. Neuroendocrinology 2007; 85 (2): 61-70
57. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007 Feb; 32 (2): 289-297
58. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008 Jun; 33 (7): 1633-1641
59. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003 Dec; 88 (12): 5875-5880
60. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyper-glycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002 Jun; 87 (6): 2918-2923
61. Yasui-Furukori N, Sato Y, Furukori H, et al. Glucose meta-bolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry 2009 Jan; 70 (1): 95-100
62. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adi-pocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007 Apr; 32 (4): 765-772
63. Baptista T, Sandia I, Lacruz A, et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007 Mar; 22 (2): 69-76
64. Baptista T, Martinez M, Lacruz A, et al. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Schizophr Res 2007 Jan; 89 (1-3): 350-352
65. Carrizo E, Fernandez V, Quintero J, et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 2008 Aug; 103 (1-3): 83-93
66. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005 May 13; 96 (9): 939-949
67. Chan JC, Tong PC, Critchley JA. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk. Semin Vasc Med 2002 Feb; 2 (1): 45-57
68. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008 Apr; 10 (2): 156-164
69. American Diabetes Association. Executive summary: stan-dards of medical care in diabetes, 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S5-11
70. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment [online]. Available from URL: http://www.diabetes.com. au/pdf/obesity-report. pdf [Accessed 2009 Jan 10]
71. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [online]. Available from URL: http://www.idf.org/ webdata/docs/MetSyndrome-FINAL.pdf [Accessed 2009 Jan 10]
72. Klein S, Allison DB, Heymsfield SB, et al. Waist cir-cumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 2007 Jun; 30 (6): 1647-1652 (Pubitemid 46871194)
73. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001 May 16; 285 (19): 2486-2497
74. Meisinger C, Doring A, Thorand B, et al. Body fat dis-tribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study.AmJClin Nutr 2006 Sep; 84 (3): 483-489 (Pubitemid 44713396)
75. World Health Organ. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Tech Rep Ser 2000; 894: i-253
76. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998 Jan; 22 (1): 39-47
77. Nguyen TT, Adair LS, He K, et al. Optimal cutoff values for overweight: using body mass index to predict incidence of hypertension in 18-to 65-year-old Chinese adults. J Nutr 2008 Jul; 138 (7): 1377-1382
78. Colin BA, Adair LS, Popkin BM. Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol 2002 Feb 15; 155 (4): 346-353
79. Mansour AA, Al-Hassan AA, Al-Jazairi MI. Cut-off values for waist circumference in rural Iraqi adults for the diagnosis of metabolic syndrome. Rural Remote Health 2007 Oct; 7 (4): 765
80. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004 May; 27 (5): 1182-1186
81. National Center for Health Statistics. 2000 CDC growth charts: United States [online]. Available from URL: http://www.cdc.gov/GrowthCharts/[Accessed 2009 Jan 10]
82. Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004 Aug; 114 (2): e198-205
83. Ng VW, Kong AP, Choi KC, et al. BMI and waist cir-cumference in predicting cardiovascular risk factor clustering in Chinese adolescents. Obesity (Silver Spring) 2007 Feb; 15 (2): 494-503
84. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardio-vascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007 Jul 10; 116 (2): 151-157
85. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007 Feb; 30 (2): 228-233
86. Su Y, Liu XM, Sun YM, et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract 2008 Jun; 62 (6): 877-882
87. American Diabetes Association. Diagnosis and classifica-tion of diabetes mellitus. Diabetes Care 2004 Jan; 27 Suppl. 1: S5-10
88. Cheng C, Kushner H, Falkner BE. The utility of fasting glucose for detection of prediabetes. Metabolism 2006 Apr; 55 (4): 434-438
89. Fonseca VA. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin Cornerstone 2007; 8 (2): 10-18
90. Henderson DC, Cagliero E, Copeland PM, et al. Elevated he-moglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007 Apr; 68 (4): 533-541
91. 2. Int J Obes Relat Metab Disord 2001 Jun; 25 (6): 793-797
92. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005 Jun; 25 (3): 255-258
93. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-1223
94. Strack T. Metformin: a review. Drugs Today (Barc) 2008 Apr; 44 (4): 303-314
95. Feig DS, Briggs GG, Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Ann Pharmaco-ther 2007 Jul; 41 (7): 1174-1180
96. Glueck CJ, Wang P. Metformin before and during preg-nancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf 2007 Mar; 6 (2): 191-198
97. Citrome L, Vreeland B. Schizophrenia, obesity, and anti-psychotic medications: what can we do? Postgrad Med 2008 Jul; 120 (2): 18-33
98. National Heart Lung and Blood Institute, National Institute of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf [Accessed 2009 Jan 10]